Unit Leader: Giovanna Roncador
Hybridoma technology for the production of monoclonal antibodies (mAbs) represents one of the most relevant methodological advances in biomedicine. The availability of mAbs has significantly improved our knowledge about cell biology and has opened up new possibilities for basic and applied research. Their use in medicine has also improved the diagnostics, prevention and treatment of a large number of diseases including cancer.
The CNIO offers to external research groups a broad array of high quality mAbs against human and/or mouse antigens. The list of currently available mAbs, together with the details on their characterization, are disclosed in our "Catalogue of Monoclonal Antibodies (PDF 3.8 MB)" and in their corresponding "Antibodies Datasheet".
For additional information please contact the Head of the Monoclonal Antibodies Unit, Giovanna Roncador at the following address: